DE399843T1 - Hilfsmittelformulierung die eine emulsion mit submikronischen oeltropfen enthaelt. - Google Patents
Hilfsmittelformulierung die eine emulsion mit submikronischen oeltropfen enthaelt.Info
- Publication number
- DE399843T1 DE399843T1 DE199090305744T DE90305744T DE399843T1 DE 399843 T1 DE399843 T1 DE 399843T1 DE 199090305744 T DE199090305744 T DE 199090305744T DE 90305744 T DE90305744 T DE 90305744T DE 399843 T1 DE399843 T1 DE 399843T1
- Authority
- DE
- Germany
- Prior art keywords
- composition according
- oil
- immunostimulant
- composition
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract 36
- 239000012752 auxiliary agent Substances 0.000 title 1
- 239000000839 emulsion Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000003022 immunostimulating agent Substances 0.000 claims abstract 14
- 239000003995 emulsifying agent Substances 0.000 claims abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 9
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims abstract 6
- 239000002671 adjuvant Substances 0.000 claims abstract 3
- 239000003599 detergent Substances 0.000 claims abstract 2
- 239000007764 o/w emulsion Substances 0.000 claims abstract 2
- 230000003308 immunostimulating effect Effects 0.000 claims 15
- 229960001438 immunostimulant agent Drugs 0.000 claims 12
- -1 a-Aminobutyryl Chemical group 0.000 claims 6
- 125000001980 alanyl group Chemical group 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229940037003 alum Drugs 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000002421 cell wall Anatomy 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 150000002632 lipids Chemical group 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 claims 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- 241001227713 Chiron Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 101710194807 Protective antigen Proteins 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000002711 cysteinyl group Chemical group 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000001939 glutaminyl group Chemical group 0.000 claims 1
- 150000002327 glycerophospholipids Chemical class 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 claims 1
- 125000001998 leucyl group Chemical group 0.000 claims 1
- 125000001288 lysyl group Chemical group 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000002073 methionyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 1
- 125000000405 phenylalanyl group Chemical group 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 125000001239 threonyl group Chemical group 0.000 claims 1
- 150000005691 triesters Chemical class 0.000 claims 1
- 125000005454 tryptophanyl group Chemical group 0.000 claims 1
- 125000002233 tyrosyl group Chemical group 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 125000002114 valyl group Chemical group 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Colloid Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (20)
1. Adjuvans-Zusammensetzung, enthaltend:
(1) ein metabolisxerbares Öl und
(2) einen Emulgator,
wobei das Öl und der Emulgator in Form einer Öl-in-Wasser-Emulsion
mit Öltröpfchen, von denen im wesentlichen alle einen Durchmesser von <1 Mikron aufweisen, vorliegen
und die Zusammensetzung kein Polyoxypropylen-Polyoxyethylen-Blockcopolymeres
enthält.
2. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß das Öl ein Öl tierischer Herkunft ist.
3. Zusammensetzung nach Anspruch 2, dadurch gekennzeichnet, daß das Öl ein ungesättigter Kohlenwasserstoff ist.
4. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß das Öl ein Terpenoid ist.
5. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß das Öl ein Öl pflanzlicher Herkunft ist.
6. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß die Zusammensetzung 0,5 bis 20 Vol.-% des Öls in einem
wäßrigen Medium umfaßt.
7. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet,
daß der Emulgator ein nichtionisches Detergens umfaßt.
8. Zusammensetzung nach Anspruch 7, dadurch gekennzeichnet,
daß der Emulgator einen Polyoxyethylensorbitanmono-, -dioder -triester oder einen Sorbitanmono-, -di- oder
-triester umfaßt.
daß der Emulgator einen Polyoxyethylensorbitanmono-, -dioder -triester oder einen Sorbitanmono-, -di- oder
-triester umfaßt.
9. Zusammensetzung nach Anspruch 0, dadurch gekennzeichnet,
daß die Zusammensetzung 0,01 bis 0,5 Gew.-% des Emulgators umfaßt.
daß die Zusammensetzung 0,01 bis 0,5 Gew.-% des Emulgators umfaßt.
10. Zusammensetzung nach Anspruch 9, dadurch gekennzeichnet,
daß die Zusammensetzung zusätzlich ein getrenntes Immunostimulans umfaßt.
daß die Zusammensetzung zusätzlich ein getrenntes Immunostimulans umfaßt.
11. Zusammensetzung nach Anspruch 10, dadurch gekennzeichnet, daß das Immunostimulans Alum oder eine Bakterienzellwand-Komponente
umfaßt.
12. Zusammensetzung nach Anspruch 11, dadurch gekennzeichnet, daß die Zusammensetzung 0,0001 bis 1,0 Gew.-% des Immunostimulans
umfaßt.
13. Zusammensetzung nach Anspruch 11, dadurch gekennzeichnet, daß das Immunostimulans ein Muramylpeptid umfaßt.
14. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet,
daß der Emulgator zusätzlich als ein Immunostimulans
wirkt.
daß der Emulgator zusätzlich als ein Immunostimulans
wirkt.
15. Zusammensetzung nach Anspruch 14, dadurch gekennzeichnet, daß die Zusammensetzung 0,01 bis 0,5 Gew.-% des Immunostimulans
umfaßt.
16. Zusammensetzung nach Anspruch 14, dadurch gekennzeichnet, daß das Immunostimulans ein lipophiles Muramylpeptid
umfaßt.
umfaßt.
17. Zusammensetzung nach Anspruch 16, dadurch gekennzeichnet,
daß das Peptid ein Muramyldipeptid oder ein Muramyltripeptid
umfaßt.
10. Zusammensetzung nach Anspruch 17, dadurch gekennzeichnet,
daß das Peptid weiterhin ein Phospholipid umfaßt.
19. Zusammensetzung nach Anspruch 18, dadurch gekennzeichnet,
daß das Phospholipid ein Phosphoglycerid umfaßt.
20. Zusammensetzung nach Anspruch 14, dadurch gekennzeichnet, daß das Peptid eine Verbindung mit der Formel
ist,
wobei R Wasserstoff oder COCI-L,;
12 3
R , R und R unabhängig voneinander Wasserstoff oder
R , R und R unabhängig voneinander Wasserstoff oder
einen Lipidrest;
R Wasserstoff oder eine Alkylgruppe;
X und Z unabhängig voneinander einen Aminoacyl-Rest,
ausgewählt aus der von Alanyl, Valyl, Leucyl, Isoleucyl,
a-Aminobutyryl, Threonyl, Methionyl, Cysteinyl, Glutamyl, Isoglutamyl, Glutaminyl, Isoglutaminyl, Aspartyl, Phenylalanyl, Tyrosyl, Tryptophanyl, Lysyl, Ornithinyl, Arginyl,
ausgewählt aus der von Alanyl, Valyl, Leucyl, Isoleucyl,
a-Aminobutyryl, Threonyl, Methionyl, Cysteinyl, Glutamyl, Isoglutamyl, Glutaminyl, Isoglutaminyl, Aspartyl, Phenylalanyl, Tyrosyl, Tryptophanyl, Lysyl, Ornithinyl, Arginyl,
Histidyl, Asparginyl/ Prolyl, Hydroxypropyl, Seryl und
Glycyl gebildeten Gruppe;
&eegr; 0 oder 1;
Y -NHCHR CH2CH2CO-, wobei R eine gegebenenfalls veresterte
oder amidierte Carboxyl-Gruppe darstellt; und
L OH, NR R , "wobei R und R unabhängig voneinander H oder
eine niedere Alkyl-Gruppe darstellen, oder ein Lipidrest
bedeuten.
21. Zusammensetzung nach Anspruch 20, dadurch gekennzeichnet, daß R Methyl, X Alanyl, und Y Isoglutaminyl bedeuten.
22. Zusammensetzung nach Anspruch 20, dadurch gekennzeichnet,
daß n=l, Z Alanyl, R
stoffatome bedeuten.
stoffatome bedeuten.
12 3 daß n=l, Z Alanyl, R Acetyl sowie R , R und R Wasser-
23. Zusammensetzung nach Anspruch 22, dadurch gekennzeichnet, daß L einen Phospholipidrest umfaßt.
24. Zusammensetzung nach Anspruch 23, dadurch gekennzeichnet,
daß der Phospholipidrest ein Diacylphosphoglycerid umfaßt.
25. Zusammensetzung nach Anspruch 20, dadurch gekennzeichnet, daß das Peptid N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanin-2[1,2-dipalmitoyl-sn-glycero-3-(hydroxy-phosphoryloxy)]ethylamid
ist.
26. Zusammensetzung nach Anspruch 20, dadurch gekennzeichnet,
1 2 daß mindestens eine der Gruppen R und R eine Acyl-Grupp
mit 1 bis 22 Kohlenstoffatomen darstellt.
27. Zusammensetzung nach Anspruch 20, dadurch gekennzeichnet,
12 3
daß mindestens eine der Gruppen R7R und R eine Acyl-
daß mindestens eine der Gruppen R7R und R eine Acyl-
Gruppe mit 14 bis 22 Kohlenstoffatomen darstellt.
20. Impfzusammensetzung, enthaltend:
20. Impfzusammensetzung, enthaltend:
(1) eine immunostimulierende Menge einer Antigen-Substanz,
und
(2) eine immunostimulierende Menge des Adjuvans nach Anspruch
1.
29. Verfahren zur Stimulierung einer Immunreaktion in einem
Wirtstier, gekennzeichnet durch eine
Verabreichung eines Schutzantigens in Anwesenheit einer immunostimulierenden Menge von metabolisierbaren Submikron-Öltröpfchen
in einer kontinuierlichen wäßrigen
Phase.
Phase.
30. Verfahren nach Anspruch 29, dadurch gekennzeichnet, daß die Öltröpfchen zusätzlich einen Emulgator enthalten.
31. Verfahren nach Anspruch 30, dadurch gekennzeichnet, daß die Öltröpfchen zusätzlich ein Immunostimulans getrennt
von dem Öl und dem Emulgator enthalten.
32. Verfahren nach Anspruch 31, dadurch gekennzeichnet, daß das Immunostimulans Alum oder eine bakterielle Zellwandkomponente
umfaßt.
33. Verfahren nach Anspruch 31, dadurch gekennzeichnet, daß das Immunostimulans ein Muramylpeptid umfaßt.
34. Verfahren nach Anspruch 30, dadurch gekennzeichnet, daß der Emulgator ebenfalls als Immunostimulans wirkt.
35. Verfahren nach Anspruch 34, dadurch gekennzeichnet, daß
das Immunostimulans ein lipophiles Muramylpeptid umfaßt.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35703589A | 1989-05-25 | 1989-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE399843T1 true DE399843T1 (de) | 1991-05-02 |
Family
ID=23404033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE199090305744T Pending DE399843T1 (de) | 1989-05-25 | 1990-05-25 | Hilfsmittelformulierung die eine emulsion mit submikronischen oeltropfen enthaelt. |
| DE69010574T Revoked DE69010574T2 (de) | 1989-05-25 | 1990-05-25 | Hilfsmittelformulierung die eine Emulsion mit submikronischen Oeltropfen enthält. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69010574T Revoked DE69010574T2 (de) | 1989-05-25 | 1990-05-25 | Hilfsmittelformulierung die eine Emulsion mit submikronischen Oeltropfen enthält. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6299884B1 (de) |
| EP (1) | EP0399843B1 (de) |
| JP (1) | JPH0832638B2 (de) |
| AT (1) | ATE108327T1 (de) |
| CA (1) | CA2017507C (de) |
| DD (1) | DD294633A5 (de) |
| DE (2) | DE399843T1 (de) |
| DK (1) | DK0399843T5 (de) |
| ES (1) | ES2033626T3 (de) |
| GR (1) | GR910300063T1 (de) |
| HK (1) | HK107695A (de) |
| HU (1) | HU212924B (de) |
| IE (1) | IE64766B1 (de) |
| PT (1) | PT94168B (de) |
| WO (1) | WO1990014837A1 (de) |
Families Citing this family (649)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364632A (en) * | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| US5200344A (en) * | 1990-11-13 | 1993-04-06 | Blaser Martin J | Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens |
| US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| ES2117052T5 (es) * | 1991-07-25 | 2004-12-01 | Idec Pharmaceuticals Corporation | Induccion de respuestas de linfocitos t citotoxicos. |
| US6197311B1 (en) | 1991-07-25 | 2001-03-06 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
| CA2083553A1 (en) * | 1991-11-25 | 1993-05-26 | Kuniharu Seki | Immunogen composition |
| ATE249838T1 (de) | 1993-05-12 | 2003-10-15 | Chiron Corp | Konserviertes motiv der hepatitis c virus e2/ns1 region |
| DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
| CA2167691A1 (en) * | 1993-08-27 | 1995-03-02 | Martin J. Blaser | Campylobacter jejuni antigens, and methods for their production and use |
| US5919466A (en) * | 1993-10-01 | 1999-07-06 | Gerbu Biotechnik Gmbh | Method for improving the yield of immunoantibodies in the vaccination of animals and humans |
| DE69431358T2 (de) * | 1993-10-22 | 2003-06-05 | Genentech Inc., San Francisco | Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien |
| US5643605A (en) * | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
| US6913767B1 (en) | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5629167A (en) | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
| WO1996009757A1 (en) * | 1994-09-28 | 1996-04-04 | Biocine Spa | Mouse model for helicobacter pylori infection |
| KR100478617B1 (ko) * | 1994-12-07 | 2005-05-16 | 아이덱 파마슈티칼즈 코포레이션 | 세포독성t-림프구반응을유도하는방법 |
| US5616342A (en) * | 1995-04-11 | 1997-04-01 | Pdt, Inc. | Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof |
| US6034073A (en) * | 1995-04-24 | 2000-03-07 | Novavax, Inc. | Solvent detergent emulsions having antiviral activity |
| US5718904A (en) * | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
| US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
| DE69737413T2 (de) | 1996-01-04 | 2007-10-31 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Bakterioferritin aus helicobacter pylori |
| WO1997029773A1 (fr) * | 1996-02-13 | 1997-08-21 | The Nisshin Oil Mills, Ltd. | Emulsion et poudre renfermant un vaccin et destinees a une administration orale, et procede de production associe |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US5980912A (en) * | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| GB9708066D0 (en) * | 1997-04-22 | 1997-06-11 | Woolcombers Group Plc | Compositions and their use |
| AU764483B2 (en) * | 1997-04-22 | 2003-08-21 | Croda Chemicals International Limited | Aqueous compositions comprising a lipid and a lanolin-derived surfactant, and their use |
| WO1999002132A2 (en) * | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| US6030619A (en) | 1997-08-27 | 2000-02-29 | Chiron Corporation | Molecular mimetics of meningococcal B epitopes |
| EP1023045A2 (de) * | 1997-10-24 | 2000-08-02 | Neorx Corporation | Verabreichungsträger für bioaktiven wirkstoffen und ihre verwendung |
| ATE476508T1 (de) | 1997-11-06 | 2010-08-15 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| DK1042001T3 (da) | 1997-12-16 | 2002-07-08 | Chiron Corp | Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner |
| US7393630B2 (en) | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
| US6165481A (en) * | 1997-12-25 | 2000-12-26 | Nippon Petrochemicals Company, Inc. | Highly pure squalane, raw material for pharmaceuticals and cosmetics prepared by using the same and method for producing the same |
| BR9906927A (pt) | 1998-01-14 | 2001-11-20 | Chiron Spa | Proteìnas de neisseria meningitidis |
| GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| BR9910089A (pt) | 1998-05-01 | 2004-06-08 | Chiron Corp | Composições e antìgenos de neisseria meningitidis |
| KR100682154B1 (ko) * | 1998-05-07 | 2007-02-12 | 코릭사 코포레이션 | 아쥬번트 조성물 및 그의 사용방법 |
| US8007815B1 (en) | 1998-05-29 | 2011-08-30 | Novartis Ag | Combination meningitidis B/C vaccines |
| WO2000003724A1 (fr) * | 1998-07-16 | 2000-01-27 | Hayashi, Akira | Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif |
| US6416763B1 (en) | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
| EP1980617A1 (de) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| SE9900496D0 (sv) * | 1999-02-12 | 1999-02-12 | Pharmatrix Ab | Vaccine formulation |
| SE9900495D0 (sv) * | 1999-02-12 | 1999-02-12 | Pharmatrix Ab | Vaccine composition |
| EP2275133A1 (de) | 1999-02-26 | 2011-01-19 | Novartis Vaccines and Diagnostics, Inc. | Verwendung von Bioklebstoffen und Impfstoff-Adjuvantien für mucosale Verabreichung von antigenem Material |
| ES2228454T3 (es) * | 1999-02-26 | 2005-04-16 | Chiron S.R.L. | Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg. |
| JP2002537102A (ja) | 1999-02-26 | 2002-11-05 | カイロン コーポレイション | 吸着された高分子および微粒子を有するミクロエマルジョン |
| ATE463578T1 (de) | 1999-04-14 | 2010-04-15 | Novartis Vaccines & Diagnostic | Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren- systeme |
| US7767216B2 (en) * | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US7655252B2 (en) | 1999-04-28 | 2010-02-02 | The Regents Of The University Of Michigan | Antimicrobial nanoemulsion compositions and methods |
| EP1228217B1 (de) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Konservierte antigene aus neisseria |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| WO2001030812A2 (en) | 1999-10-27 | 2001-05-03 | Chiron Corporation | Activation of hcv-specific t cells |
| AU784203B2 (en) | 1999-10-29 | 2006-02-23 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| DK1248647T3 (da) | 2000-01-17 | 2010-09-27 | Novartis Vaccines & Diagnostic | Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner |
| BR0110278A (pt) | 2000-04-25 | 2003-01-07 | Evolutec Ltd | Composição de vacina, anticorpo ou anti-soro, métodos de produção de um anticorpo ou de um anti-soro e de imunização de um animal contra um ectoparasita que se alimenta de sangue, proteìna de cemento de carrapato, e, uso de uma proteìna de cemento de carrapato |
| US6753015B2 (en) | 2000-09-28 | 2004-06-22 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
| DK2266603T3 (da) | 2000-10-18 | 2012-11-05 | Glaxosmithkline Biolog Sa | Tumorvacciner |
| AU1412702A (en) | 2000-10-27 | 2002-05-06 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a and b |
| JP2004535765A (ja) | 2000-12-07 | 2004-12-02 | カイロン コーポレイション | 前立腺癌においてアップレギュレートされた内因性レトロウイルス |
| WO2002080982A2 (en) | 2001-01-12 | 2002-10-17 | Chiron Corporation | Nucleic acid mucosal immunization |
| WO2002067899A1 (en) * | 2001-02-28 | 2002-09-06 | Akzo Nobel N.V. | Injectable water-in-oil emulsions |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| AU2002312011B2 (en) | 2001-05-22 | 2008-04-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| WO2004030608A2 (en) * | 2001-06-05 | 2004-04-15 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
| CZ20033515A3 (cs) * | 2001-06-29 | 2005-01-12 | Chiron Corporation | Kompozice vakcíny HCV E1E2 |
| EP1411770A4 (de) | 2001-07-05 | 2006-05-10 | Chiron Corp | Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung |
| JP4302513B2 (ja) | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| US20030026783A1 (en) | 2001-08-03 | 2003-02-06 | Amine Abina | Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US20050106162A1 (en) | 2001-12-12 | 2005-05-19 | Guido Grandi | Immunisation against chlamydia trachomatis |
| GB0201736D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | DNA dosage forms |
| AU2003215316A1 (en) | 2002-02-20 | 2003-09-09 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
| EP2360185A3 (de) | 2002-02-25 | 2012-01-11 | Elan Pharmaceuticals Inc. | Verabreichung von Wirkstoffen zur Behandlung von Entzündungen |
| CA2477675C (en) | 2002-03-05 | 2013-05-21 | Ramot At Tel-Aviv University Ltd. | Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
| AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
| AU2003254792A1 (en) * | 2002-08-02 | 2004-02-23 | Sumitomo Pharmaceuticals Company, Limited | Bacterial cell wall skeleton component preparaion |
| KR20050052467A (ko) * | 2002-08-12 | 2005-06-02 | 다이나박스 테크놀로지 코퍼레이션 | 면역조절 조성물, 이의 제조방법 및 이의 이용방법 |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| WO2010011999A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
| EP2301573A1 (de) | 2002-10-01 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Zusammensetzungen gegen Krebs und Infektionskrankheiten und Anwendungsverfahren dafür |
| EP1565583A4 (de) | 2002-10-07 | 2007-11-21 | Novartis Vaccines & Diagnostic | Hiv-vakzine-formulierungen |
| PT2353608T (pt) | 2002-10-11 | 2020-03-11 | Novartis Vaccines And Diagnostics S R L | Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| EP1562982B1 (de) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unerwartete oberflächenproteine in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| WO2004060396A2 (en) * | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| US10272147B2 (en) | 2003-01-30 | 2019-04-30 | Glaxosmithkline Biologicals S.A. | Injectable vaccines against multiple meningococcal serogroups |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| CN1767854B (zh) * | 2003-04-04 | 2013-07-24 | 硕腾P有限责任公司 | 微流化水包油乳剂及疫苗组合物 |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
| EP2301571A1 (de) | 2003-05-07 | 2011-03-30 | Sanofi Pasteur Inc. | Tetravalenter impstoff mit erhöhten Immunogenicität gegen Neisseria meningitidis. |
| US20050002957A1 (en) | 2003-05-07 | 2005-01-06 | Ryall Robert P. | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| JP4820291B2 (ja) | 2003-05-19 | 2011-11-24 | エラン ファーマシューティカルズ，インコーポレイテッド | レヴィー小体病におけるαシヌクレインの切断断片 |
| JP5557415B2 (ja) | 2003-06-02 | 2014-07-23 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物 |
| US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
| JP4875490B2 (ja) | 2003-07-31 | 2012-02-15 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物 |
| US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| PT1961426E (pt) | 2003-10-02 | 2011-06-28 | Novartis Vaccines & Diagnostic | Vacinas combinadas contra a meningite |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| US20050074469A1 (en) * | 2003-10-03 | 2005-04-07 | Charles Signorino | Stable lipophilic emulsions for acrylic coating and method of making |
| US20050158329A1 (en) * | 2004-01-21 | 2005-07-21 | Ghosh Swapan K. | Novel phytol derived immunoadjuvants and their use in vaccine formulations |
| CA2559371C (en) | 2004-03-09 | 2014-07-08 | Chiron Corporation | Influenza virus vaccines |
| PL1742659T3 (pl) | 2004-04-05 | 2013-08-30 | Zoetis Services Llc | Poddane mikrofluidyzacji emulsje typu olej w wodzie oraz kompozycje szczepionek |
| WO2005102369A1 (ja) * | 2004-04-22 | 2005-11-03 | Dainippon Sumitomo Pharma Co., Ltd. | 細菌細胞壁骨格成分を含有する製剤 |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| PL1740217T3 (pl) | 2004-04-30 | 2012-03-30 | Novartis Ag | Szczepienie koniugatem meningokokowym |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| WO2006078294A2 (en) | 2004-05-21 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Alphavirus vectors for respiratory pathogen vaccines |
| KR20070029708A (ko) | 2004-05-21 | 2007-03-14 | 와이어쓰 | 스타필로코커스 아우레우스의 변형 피브로넥틴-결합 단백질 |
| EP2277595A3 (de) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Verbindungen zur Immunopotenzierung |
| CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| FR2873386B1 (fr) | 2004-07-22 | 2011-01-14 | Agence Francaise De Securite Sanitaire Des Aliments Afssa | Composition vaccinale contre le rhodococcus equi |
| EP2612679A1 (de) | 2004-07-29 | 2013-07-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogene Zusammensetzungen für grampositive Bakterien wie etwa Streptococcus agalactiae |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| AU2005279821A1 (en) | 2004-08-30 | 2006-03-09 | Sanofi Pasteur, Inc. | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| KR20070095868A (ko) | 2004-09-21 | 2007-10-01 | 사노피 파스퇴르 인크 | 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신 |
| TWI365074B (en) * | 2004-10-07 | 2012-06-01 | Wyeth Corp | Multivalent avian influenza vaccines |
| EP2465872A3 (de) | 2004-10-25 | 2012-12-19 | Merck Sharp & Dohme Corporation | Anti-ADDL-Antikörper und ihre Verwendungen |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| US20100015211A1 (en) | 2004-11-01 | 2010-01-21 | Barnett Susan W | Combination Approaches For Generating Immune Responses |
| CA2586690A1 (en) * | 2004-11-03 | 2006-06-15 | Novartis Vaccines And Diagnostics, Inc. | Influenza vaccination |
| TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
| NZ555937A (en) | 2005-01-27 | 2009-05-31 | Childrens Hosp & Res Ct Oak | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| DK2351772T3 (en) | 2005-02-18 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Proteins and nucleic acids from meningitis / sepsis-associated Escherichia coli |
| TW200722101A (en) * | 2005-03-23 | 2007-06-16 | Glaxosmithkline Biolog Sa | Novel composition |
| EP2425856A1 (de) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalente Pneumokokken-Polysaccharidproteinkonjugatzusammensetzung |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP1871349A1 (de) * | 2005-04-11 | 2008-01-02 | Nanobio Corporation | Quartäre ammoniumhalogenide zur behandlung von infektionskrankheiten |
| FR2888117B1 (fr) * | 2005-07-07 | 2009-10-09 | Sanofi Pasteur Sa | Composition vaccinale comprenant une emulsion thermoreversible |
| AR054822A1 (es) * | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| US8703095B2 (en) * | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| ATE526036T1 (de) * | 2005-08-02 | 2011-10-15 | Novartis Vaccines & Diagnostic | Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen |
| CA2618974C (en) * | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
| US7797337B2 (en) * | 2005-09-29 | 2010-09-14 | Scenera Technologies, Llc | Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource |
| EP1954309A2 (de) * | 2005-10-17 | 2008-08-13 | Novartis AG | Multiclade-hiv-vakzine |
| US20110223197A1 (en) | 2005-10-18 | 2011-09-15 | Novartis Vaccines And Diagnostics Inc. | Mucosal and Systemic Immunization with Alphavirus Replicon Particles |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| PL1945252T3 (pl) * | 2005-11-04 | 2013-11-29 | Seqirus Uk Ltd | Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant |
| JP2009514839A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | サイトカイン誘導剤を含むアジュバントインフルエンザワクチン |
| JP2009514844A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション |
| NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| AU2011213757B2 (en) * | 2005-11-04 | 2013-07-25 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| US8900180B2 (en) * | 2005-11-18 | 2014-12-02 | 3M Innovative Properties Company | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
| JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| LT2384765T (lt) | 2005-12-22 | 2017-01-10 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae vakcina |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| JP5214464B2 (ja) | 2005-12-28 | 2013-06-19 | アドバンスド バイオニュートリション コーポレーション | 多糖類、糖類およびポリオール類の乾燥マトリックスを含む、ガラス形態の、プロバイオティクス細菌用送達媒体およびその製造方法 |
| FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| JP6087041B2 (ja) | 2006-01-27 | 2017-03-08 | ノバルティス アーゲー | 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン |
| CA2647100A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Methods for the preparation of imidazole-containing compounds |
| CA2646891A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2010537B1 (de) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazochinoxalinverbindungen als immunmodulatoren |
| JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
| JP2009531387A (ja) | 2006-03-30 | 2009-09-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| SG173336A1 (en) | 2006-03-31 | 2011-08-29 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| EP2035448A4 (de) | 2006-06-01 | 2010-11-03 | Elan Pharm Inc | Neuroaktive fragmente von app |
| ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
| RU2450019C2 (ru) | 2006-06-29 | 2012-05-10 | Новартис Аг | Полипептиды из neisseria meningitidis |
| SI2043682T1 (sl) | 2006-07-17 | 2014-07-31 | Glaxosmithkline Biologicals S.A. | Influenčno cepivo |
| PL2043682T3 (pl) | 2006-07-17 | 2014-09-30 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
| WO2008094188A2 (en) | 2006-07-17 | 2008-08-07 | Anza Therapeutics, Inc. | Methods and compositions using listeria for enhancing immunogenicity by prime boost |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| PT2520168E (pt) | 2006-07-21 | 2014-04-29 | California Inst Of Techn | Administração de gene alvo para vacinação de células dendríticas |
| CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| CA2663196A1 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PL2468300T3 (pl) | 2006-09-26 | 2018-04-30 | Infectious Disease Research Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
| PL2086582T3 (pl) | 2006-10-12 | 2013-04-30 | Glaxosmithkline Biologicals Sa | Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie |
| WO2008043774A1 (en) | 2006-10-12 | 2008-04-17 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
| GB0622282D0 (en) | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
| EP2679240A1 (de) | 2006-12-06 | 2014-01-01 | Novartis AG | Impfstoffe mit Antigen aus vier Stämmen des Influenzavirus |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| PT2118300E (pt) | 2007-02-23 | 2015-09-22 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
| JP5558834B2 (ja) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
| CA2688284A1 (en) | 2007-05-25 | 2008-12-04 | Novartis Ag | Streptococcus pneumoniae pilus antigens |
| EA020817B1 (ru) | 2007-06-26 | 2015-02-27 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| EP2182983B1 (de) | 2007-07-27 | 2014-05-21 | Janssen Alzheimer Immunotherapy | Behandlung von amyloidogenen erkrankungen mittels humanisierter anti-abeta antikörper |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| MX2010001284A (es) | 2007-08-02 | 2010-08-31 | Biondvax Pharmaceuticals Ltd | Vacunas contra la influenza con multiepitope multimerico. |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| RU2468034C2 (ru) | 2007-08-27 | 2012-11-27 | ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи | Иммуногенные композиции и способы |
| MX2010002773A (es) | 2007-09-12 | 2010-03-31 | Novartis Ag | Antigenos mutantes de gas57 y anticuerpos de gas57. |
| JP5731198B2 (ja) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用 |
| WO2009085355A2 (en) | 2007-10-01 | 2009-07-09 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| ATE553774T1 (de) | 2007-10-19 | 2012-05-15 | Novartis Ag | Meningokokkenimpfstoffformulierungen |
| JP5588874B2 (ja) † | 2007-11-26 | 2014-09-10 | ノバルティス アーゲー | アジュバント添加されたグルカン |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| ES2664753T3 (es) | 2007-12-07 | 2018-04-23 | Glaxosmithkline Biologicals Sa | Composiciones de inducción de respuestas inmunes |
| US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
| WO2009117035A1 (en) | 2007-12-19 | 2009-09-24 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Soluble forms of hendra and nipah virus f glycoprotein and uses thereof |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| RU2498994C2 (ru) | 2007-12-21 | 2013-11-20 | Новартис Аг | Мутантные формы стрептолизина о |
| US8092813B1 (en) * | 2007-12-28 | 2012-01-10 | Novartis Ag | Polychlorinated biphenyls and squalene-containing adjuvants |
| ES2544679T3 (es) | 2007-12-28 | 2015-09-02 | Prothena Biosciences Limited | Tratamiento y profilaxis de la amiloidosis |
| US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| CA2717870A1 (en) | 2008-03-10 | 2009-09-17 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
| WO2009115917A2 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
| ES2553113T3 (es) | 2008-04-16 | 2015-12-04 | Glaxosmithkline Biologicals S.A. | Vacuna |
| WO2009146523A1 (en) * | 2008-06-05 | 2009-12-10 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| JP2011525113A (ja) | 2008-06-20 | 2011-09-15 | ワイス・エルエルシー | β−溶血性連鎖球菌株由来のＯＲＦ１３５８の組成物および使用方法 |
| KR101707569B1 (ko) | 2008-08-01 | 2017-02-16 | 감마 백신즈 피티와이 리미티드 | 인플루엔자 백신 |
| US11236366B2 (en) | 2008-08-28 | 2022-02-01 | Novartis Ag | Production of squalene from hyper-producing yeasts |
| CN102159242A (zh) | 2008-09-18 | 2011-08-17 | 诺华有限公司 | 疫苗佐剂组合 |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| CN102239253A (zh) | 2008-12-03 | 2011-11-09 | 普罗蒂亚维仕尼科技有限公司 | 谷氨酰tRNA合成酶（GtS）片段 |
| PE20142330A1 (es) | 2008-12-09 | 2015-01-14 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| US9884105B2 (en) | 2008-12-16 | 2018-02-06 | Ology Bioservices, Inc. | Production of viral vaccine |
| BRPI1005670A8 (pt) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | composições adjuvantes e processos de uso. |
| US8465751B2 (en) | 2009-01-12 | 2013-06-18 | Novartis Ag | Cna—B domain antigens in vaccines against gram positive bacteria |
| KR20110117654A (ko) | 2009-01-13 | 2011-10-27 | 트랜스진 에스.에이. | 면역 자극에 있어서의 사카로미세스 세레비지아에 미토콘드리아 핵산 분획물의 용도 |
| SI2396030T1 (sl) | 2009-02-10 | 2015-12-31 | Novartis Ag | Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo |
| US20120093860A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
| EA023662B1 (ru) | 2009-02-10 | 2016-06-30 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
| RU2011140508A (ru) | 2009-03-06 | 2013-04-20 | Новартис Аг | Антигены хламидии |
| ES2593862T3 (es) | 2009-03-09 | 2016-12-13 | Molecular Express, Inc. | Métodos y composiciones de formulación liposomal de antígenos y usos de los mismos |
| CN102438649A (zh) | 2009-03-24 | 2012-05-02 | 诺华有限公司 | 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物 |
| EP3263128A3 (de) | 2009-04-14 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Zusammensetzungen zur immunisierung gegen staphylococcus aureus |
| CA2763816A1 (en) * | 2009-04-27 | 2010-11-04 | Novartis Ag | Adjuvanted vaccines for protecting against influenza |
| AU2010250832B2 (en) | 2009-05-21 | 2013-10-03 | Seqirus UK Limited | Reverse genetics using non-endogenous pol I promoters |
| NZ597053A (en) | 2009-05-26 | 2014-02-28 | Advanced Bionutrition Corp | Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making |
| WO2010136896A1 (en) | 2009-05-29 | 2010-12-02 | Novartis Ag | Assays for influenza virus hemagglutinins |
| US8722064B2 (en) | 2009-06-05 | 2014-05-13 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| EA032675B1 (ru) | 2009-06-10 | 2019-07-31 | Нью-Йорк Юниверсити | Способ и композиции для лечения болезни альцгеймера и других таупатий |
| EP2944320A1 (de) | 2009-06-15 | 2015-11-18 | National University of Singapore | Influenzaimpfstoff, zusammensetzung und verfahren zur verwendung |
| CN102625713A (zh) | 2009-06-22 | 2012-08-01 | 惠氏有限责任公司 | 用于制备金黄色葡萄球菌血清型5和8荚膜多糖缀合物免疫原性组合物的组合物和方法 |
| EP3238742A1 (de) | 2009-06-22 | 2017-11-01 | Wyeth LLC | Immunogene staphylococcus aureus-antigenzusammensetzungen |
| SG177533A1 (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens |
| TW201116294A (en) | 2009-07-15 | 2011-05-16 | Novartis Ag | RSV F protein compositions and methods for making same |
| AU2010272243A1 (en) | 2009-07-16 | 2012-03-08 | Novartis Ag | Detoxified Escherichia coli immunogens |
| EP2453903B1 (de) | 2009-07-17 | 2016-08-17 | Industry Academic Cooperation Foundation, Hallym University | Immunstimulatorische zusammensetzung mit liposomgekapselten oligonukleotiden und epitopen |
| LT2770061T (lt) | 2009-07-24 | 2018-12-27 | Immune Design Corp. | Neįsiterpiantis lentiviruso vektorius |
| CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| US9821052B2 (en) | 2009-07-31 | 2017-11-21 | Seqirus UK Limited | Reverse genetics systems |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2470204B1 (de) | 2009-08-27 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Hybridpolypeptide mit meningokokken-fhbp-sequenzen |
| DK2473605T3 (en) | 2009-09-03 | 2018-05-28 | Pfizer Vaccines Llc | PCSK9-VACCINE |
| CA2773637A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| PL2477987T3 (pl) | 2009-09-14 | 2018-06-29 | Gilead Sciences, Inc. | Modulatory receptorów toll-podobnych |
| GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
| GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
| BR112012009014B8 (pt) | 2009-09-30 | 2022-10-04 | Novartis Ag | Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica |
| AU2010302344A1 (en) | 2009-09-30 | 2012-04-26 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| EP2485753A4 (de) | 2009-10-09 | 2013-12-11 | Cbio Ltd | Chaperonin-10-varianten |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| CN102741399A (zh) | 2009-10-20 | 2012-10-17 | 诺华有限公司 | 用于病毒拯救的改良反向遗传方法 |
| WO2011051893A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
| JP5754860B2 (ja) | 2009-12-03 | 2015-07-29 | ノバルティス アーゲー | ワクチンアジュバントの製造の間の親水性濾過 |
| AU2010325751B2 (en) | 2009-12-03 | 2014-05-08 | Seqirus UK Limited | Arranging interaction and back pressure chambers for microfluidization |
| SI2506834T1 (sl) | 2009-12-03 | 2016-04-29 | Novartis Ag | Cirkulacija sestavin med homogenizacijo in mikrofluidizacijo emulzij |
| DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| CL2012001399A1 (es) | 2009-12-03 | 2013-03-08 | Novartis Ag | Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion. |
| US20110159031A1 (en) | 2009-12-22 | 2011-06-30 | Baxter International Inc. | Vaccine to Influenza A Virus |
| NZ629256A (en) | 2009-12-22 | 2016-02-26 | Celldex Therapeutics Inc | Vaccine compositions |
| EP2519265B1 (de) | 2009-12-30 | 2018-11-14 | GlaxoSmithKline Biologicals SA | An e.coli-trägerproteine konjugierte polysaccharidimmunogene |
| US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
| RU2535869C2 (ru) | 2010-01-28 | 2014-12-20 | Эдванст Бионутришн Корпорейшн | Сухая стекловидная композиция для стабилизации и защиты биологически активного материала и способ ее получения |
| EP2353609A1 (de) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunisierungszusammensetzungen und -verfahren |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
| ES2910199T3 (es) | 2010-03-30 | 2022-05-11 | Childrens Hospital & Res Center At Oakland | Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| US9597326B2 (en) | 2010-04-13 | 2017-03-21 | Glaxosmithkline Biologicals Sa | Benzonapthyridine compositions and uses thereof |
| EP2620423B2 (de) | 2010-05-12 | 2019-07-31 | Novartis AG | Verbesserte Verfahren zur Herstellung von Squalen |
| AU2011254204B2 (en) | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
| US9161974B2 (en) | 2010-05-23 | 2015-10-20 | Aduro Biotech, Inc. | Methods and compositions using listeria for adjuvant treatment of cancer |
| KR20130121699A (ko) | 2010-05-28 | 2013-11-06 | 테트리스 온라인, 인코포레이티드 | 상호작용 혼성 비동기 컴퓨터 게임 기반구조 |
| KR101609032B1 (ko) | 2010-06-04 | 2016-04-04 | 와이어쓰 엘엘씨 | 스트렙토코커스 뉴모니아 백신 제제 |
| WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| EP2576613A1 (de) | 2010-06-07 | 2013-04-10 | Pfizer Inc. | Her-2-peptide und impfstoffe |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| JP6025721B2 (ja) | 2010-07-06 | 2016-11-16 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| KR101842301B1 (ko) | 2010-07-14 | 2018-03-26 | 머크 샤프 앤드 돔 코포레이션 | 항-ａｄｄｌ 모노클로날 항체 및 그의 용도 |
| HRP20240965T1 (hr) | 2010-08-23 | 2024-10-25 | Wyeth Llc | Stabilne formulacije antigena rlp2086 iz bakterije neisseria meningitidis |
| CN103957931B (zh) | 2010-09-03 | 2017-10-24 | 瓦尔内瓦奥地利有限责任公司 | 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途 |
| PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| CN103269713B (zh) | 2010-10-11 | 2016-01-20 | 诺华有限公司 | 抗原递送平台 |
| GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| PT2654784T (pt) | 2010-12-22 | 2017-02-13 | Wyeth Llc | Composições imunogénicas estáveis de antigénios de staphylococcus aureus |
| WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| SI2667892T1 (sl) | 2011-01-26 | 2019-05-31 | Glaxosmithkline Biologicals Sa | Imunizacijski režim proti RSV |
| EP2667891B1 (de) | 2011-01-27 | 2021-10-06 | Gamma Vaccines Pty Limited | Kombinationsimpfstoffe |
| CA2826920A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
| CA2828068C (en) | 2011-02-22 | 2019-03-19 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| CN103533954B (zh) | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | 含较低剂量的抗原和/或佐剂的联合疫苗 |
| US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP3406628A1 (de) | 2011-04-08 | 2018-11-28 | Evaxion Biotech ApS | In impfstoffen gegen staphylococcus aureus nützliche proteine und nukleinsäuren |
| JP2014518620A (ja) | 2011-04-26 | 2014-08-07 | モレキュラー エクスプレス，インコーポレイテッド | リポソーム製剤 |
| EP2701743A4 (de) | 2011-04-27 | 2015-08-19 | Univ Northwestern | Für pathologische tau-dimere und präfibrilläre pathologische tau-oligomere selektive antikörper und ihre verwendungen bei der anwendung, diagnose und überwachung von tauopathien |
| WO2012149307A2 (en) | 2011-04-27 | 2012-11-01 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
| SG194755A1 (en) | 2011-05-13 | 2013-12-30 | Novartis Ag | Pre-fusion rsv f antigens |
| AU2012272652B2 (en) | 2011-06-24 | 2017-06-01 | Epitogenesis Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
| ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
| RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
| WO2013006842A2 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| EP3854413A1 (de) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogene kombinationszusammensetzungen und ihre verwendung |
| AU2012280901B2 (en) | 2011-07-06 | 2016-11-10 | Glaxosmithkline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
| CN103764171B (zh) | 2011-07-08 | 2016-08-17 | 诺华股份有限公司 | 酪氨酸连接方法 |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| MX352522B (es) | 2011-07-26 | 2017-11-15 | Univ Mexico Nac Autonoma | USO DE PEPTIDO Gk-1 EXPRESADO EN EL FAGO FILAMENTOSO M13 PARA LA ELABORACION DE PRODUCTOS FARMACEUTICOS QUE AUMENTAN LA EFICIENCIA DE LA RESPUESTA INMUNE INDUCIDA POR ANTIGENOS VACUNALES O PATOGENOS. |
| EP3329936A1 (de) | 2011-08-22 | 2018-06-06 | Nanobio Corporation | Impfstoff gegen den herpes-simplex-virus als nanoemulsion |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| CN104093421A (zh) | 2011-09-09 | 2014-10-08 | 纳诺碧欧公司 | 纳米乳液呼吸道合胞病毒(rsv)亚单位疫苗 |
| TR201909110T4 (tr) | 2011-09-14 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler. |
| US9511130B2 (en) | 2011-09-14 | 2016-12-06 | Glaxosmithkline Biologicals Sa | Escherichia coli vaccine combination |
| EP3275461A1 (de) | 2011-09-19 | 2018-01-31 | Axon Neuroscience SE | Proteinbasierte therapie und diagnose von tau-vermittelter pathologie im bereich von morbus alzheimer |
| EP2573100A1 (de) | 2011-09-23 | 2013-03-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Totalsynthese des Kern-Tetrasaccharids des Lipopolysaccharids von Neisseria meningitidis |
| BR112014008694A2 (pt) | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| WO2013053899A1 (en) | 2011-10-12 | 2013-04-18 | Moeller Niels Iversen | Peptides derived from campylobacter jejuni and their use in vaccination |
| US20140348863A1 (en) | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| WO2013068949A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| RU2014124154A (ru) | 2011-11-14 | 2015-12-27 | Новартис Аг | Иммуногенные комплексы полианионных карбомеров и полипептидов env и способы их получения и применения |
| US9452211B2 (en) | 2011-11-28 | 2016-09-27 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| EP2788477A2 (de) | 2011-12-07 | 2014-10-15 | Institut Pasteur | Identifizierung des porcinen parecho-like virus und anwendungen |
| AU2012349753A1 (en) | 2011-12-08 | 2014-06-19 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| US20140335507A1 (en) | 2011-12-12 | 2014-11-13 | Novartis Ag | Assays for influenza virus hemagglutinins |
| CN104023744A (zh) | 2011-12-23 | 2014-09-03 | 诺华股份有限公司 | 用于针对金黄色葡萄球菌免疫的稳定组合物 |
| CN104203272A (zh) | 2012-01-26 | 2014-12-10 | 长角牛疫苗和诊断有限责任公司 | 复合抗原序列及疫苗 |
| EP2811981B1 (de) | 2012-02-07 | 2019-05-08 | Infectious Disease Research Institute | Verbesserte hilfsstoffformulierungen mit tlr4-agonisten und verwendungsverfahren dafür |
| MX2014010011A (es) | 2012-02-24 | 2014-09-08 | Novartis Ag | Proteinas y composiciones de pilus. |
| WO2013087945A2 (en) | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
| WO2013132041A2 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| SG10201602558UA (en) | 2012-03-09 | 2016-05-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| EP2827895B1 (de) | 2012-03-22 | 2017-08-09 | Janssen Vaccines & Prevention B.V. | Impfstoff gegen rsv |
| CA2868120C (en) | 2012-03-23 | 2019-02-19 | Pitney Pharmaceuticals Pty Limited | Kinase inhibitors for the treatment of cancer |
| GB201205189D0 (en) | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
| EP3480316B1 (de) | 2012-03-30 | 2022-09-14 | Immune Design Corp. | Lentivirale vektorpartikel mit verbesserter transduktionseffizienz for dc-sign exprimierende zellen |
| EP3492095A1 (de) | 2012-04-01 | 2019-06-05 | Technion Research & Development Foundation Limited | Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper |
| US20150050311A1 (en) | 2012-04-05 | 2015-02-19 | Ludwig-Maximilians-Universitat München | Novel method for the preparation of a strain-adapted vaccine |
| US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
| ES2837825T3 (es) | 2012-04-26 | 2021-07-01 | Glaxosmithkline Biologicals Sa | Antígenos y combinaciones de antígenos |
| EP2844282B1 (de) | 2012-05-04 | 2019-06-12 | Pfizer Inc | Prostata-assoziierte antigene und immuntherapieschemata auf impfstoffbasis |
| ES2787455T3 (es) | 2012-05-16 | 2020-10-16 | Immune Design Corp | Vacunas para el VHS-2 |
| SG11201407440WA (en) | 2012-05-22 | 2014-12-30 | Novartis Ag | Meningococcus serogroup x conjugate |
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| US20150161359A1 (en) | 2012-06-04 | 2015-06-11 | Novartis Ag | Methods for safety testing |
| CA2875683A1 (en) | 2012-06-05 | 2013-12-12 | The Australian National University | Vaccination with interleukin-4 antagonists |
| KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| CA2877986A1 (en) | 2012-06-27 | 2014-01-03 | Orban Biotech Llc | Ctla4 fusion proteins for the treatment of diabetes |
| EP2870238A4 (de) | 2012-07-05 | 2016-03-09 | Ohio State Innovation Foundation | Zusammensetzungen und verfahren in zusammenhang mit viralen impfstoffen |
| EP2869842A1 (de) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogene zusammensetzungen und verwendungen davon |
| SG11201500439RA (en) | 2012-07-24 | 2015-02-27 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| US20150196631A1 (en) | 2012-07-24 | 2015-07-16 | Sanofi Pasteur | Vaccine compositions |
| DK2880053T3 (da) | 2012-08-01 | 2020-05-11 | Ikaika Therapeutics Llc | Lindring af vævsskade og fibrose via anti-LTBP4-antistof |
| KR102124392B1 (ko) | 2012-08-06 | 2020-06-19 | 피트니 파마슈티컬스 피티와이 리미티드 | mTOR 경로 관련 질병 치료를 위한 화합물 |
| SI2885007T1 (sl) | 2012-08-16 | 2018-12-31 | Pfizer Inc. | Postopki in kompozicije glikokonjugacij |
| EP2890395A1 (de) | 2012-08-31 | 2015-07-08 | Novartis AG | Stabilisierte proteine zur immunisierung gegen staphylococcus aureus |
| JP6435261B2 (ja) | 2012-08-31 | 2018-12-05 | ノバルティス アーゲー | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質 |
| RU2015106930A (ru) | 2012-09-06 | 2016-10-20 | Новартис Аг | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
| MX363529B (es) | 2012-09-18 | 2019-03-27 | Novartis Ag | Vesículas de membrana externa. |
| CN105307684A (zh) | 2012-10-02 | 2016-02-03 | 葛兰素史密丝克莱恩生物有限公司 | 非直链糖缀合物 |
| WO2014053612A1 (en) | 2012-10-03 | 2014-04-10 | Novartis Ag | Immunogenic composition |
| WO2014055825A1 (en) | 2012-10-04 | 2014-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A formulation of mycobacterial components as an adjuvant for inducing th17 responses |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| CN104918634A (zh) | 2012-10-12 | 2015-09-16 | 葛兰素史密丝克莱恩生物有限公司 | 用于组合疫苗的非交联无细胞百日咳抗原 |
| ES2826555T3 (es) | 2012-11-30 | 2021-05-18 | Glaxosmithkline Biologicals Sa | Antígenos de Pseudomonas y combinación de antígenos |
| WO2014083194A1 (en) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
| AU2013354219A1 (en) | 2012-12-03 | 2015-07-02 | Novartis Ag | Reassortant influenza a viren |
| WO2014086787A1 (en) | 2012-12-05 | 2014-06-12 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| WO2014094041A1 (en) | 2012-12-17 | 2014-06-26 | Pitney Pharmaceuticals Pty Limited | Treatment of diseases involving mucin |
| CN105007935A (zh) | 2012-12-18 | 2015-10-28 | 葛兰素史密丝克莱恩生物有限公司 | 用于保护免于白喉和/或破伤风的缀合物 |
| PT3363806T (pt) | 2012-12-20 | 2022-12-16 | Pfizer | Processo de glicoconjugação |
| EP2934578B1 (de) | 2012-12-24 | 2018-11-21 | Northern Sydney Local Health District | Impfstoffe zur krebsbehandlung und zusammensetzungen zur erhöhung der impfstoffwirksamkeit |
| WO2014113541A1 (en) | 2013-01-16 | 2014-07-24 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Attenuated chlamydia vaccine |
| EP2953638B1 (de) | 2013-02-07 | 2023-07-05 | Children's Medical Center Corporation | Proteinantigene zum schutz gegen pneumokokkenkolonisation und/oder -befall |
| NZ630868A (en) | 2013-03-08 | 2017-02-24 | Janssen Vaccines & Prevention Bv | Acellular pertussis vaccine |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| CN105338999B (zh) | 2013-03-13 | 2020-02-28 | 诺华股份有限公司 | 乙型流感病毒重配 |
| DK2988780T3 (en) | 2013-04-25 | 2019-04-08 | Janssen Vaccines & Prevention Bv | STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES |
| KR20160030097A (ko) | 2013-05-10 | 2016-03-16 | 노파르티스 아게 | 인플루엔자 백신에서 기면증 위험의 방지 |
| JP6549560B2 (ja) | 2013-05-14 | 2019-07-24 | 上海 ハイチャーム インコーポレーテッドＳｈａｎｇｈａｉ Ｈｙｃｈａｒｍ Ｉｎｃ． | 低免疫原性タンパク質に対するエピトープワクチンおよびその製造方法と使用 |
| WO2015132619A1 (en) | 2013-05-15 | 2015-09-11 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
| AU2014273173B2 (en) | 2013-05-30 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| AU2014276418A1 (en) | 2013-06-06 | 2016-01-21 | Novartis Ag | Influenza virus reassortment |
| SG11201510216RA (en) | 2013-06-17 | 2016-01-28 | Crucell Holland Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| EP3016968B1 (de) | 2013-07-01 | 2019-06-26 | Newsouth Innovations Pty Limited | Diagnose und behandlung von autoimmunkrankheiten |
| US9975925B2 (en) | 2013-08-28 | 2018-05-22 | Glaxosmithkline Biologicals S.A. | Influenza antigens and antibodies |
| WO2015033251A2 (en) | 2013-09-08 | 2015-03-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP2851066A1 (de) | 2013-09-23 | 2015-03-25 | LTS LOHMANN Therapie-Systeme AG | Fixierung von Impfstoffformulierungen auf Einrichtungen zur epidermalen Immunisierung durch ölige Adjuvantien |
| EP2870974A1 (de) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella-Konjugatimpfstoffe |
| WO2015075635A2 (en) | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| WO2015082536A1 (en) | 2013-12-03 | 2015-06-11 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| IL246456B2 (en) | 2013-12-31 | 2024-06-01 | Access To Advanced Health Inst | Formulations will be assembled into a single vial |
| EA201691452A1 (ru) | 2014-01-21 | 2016-12-30 | Иммьюн Дизайн Корп. | Композиции для применения в лечении аллергических состояний |
| CA2937184A1 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
| JP6585624B2 (ja) | 2014-01-21 | 2019-10-02 | ファイザー・インク | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート |
| WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
| EP3104877B1 (de) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Pcsk9-impfstoff und verfahren zur verwendung davon |
| ES2701169T3 (es) | 2014-02-14 | 2019-02-21 | Pfizer | Conjugados glucoproteicos inmunogénicos |
| CA2939093A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| CN106535930A (zh) | 2014-03-11 | 2017-03-22 | 明尼苏达大学董事会 | 猪流行性腹泻病毒疫苗及其使用方法 |
| BE1022744B1 (fr) | 2014-03-26 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Antigenes staphylococciques mutants |
| JP6550072B2 (ja) | 2014-04-03 | 2019-07-24 | バイオンドバックス ファーマシューティカルズ リミテッド | 多量体マルチエピトープインフルエンザポリペプチドの組成物及びそれらの生成 |
| WO2015173133A1 (en) | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| CN105288614A (zh) * | 2014-06-18 | 2016-02-03 | 潘皓 | 一种疫苗组合物及其制备方法 |
| WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
| EA038400B1 (ru) | 2014-07-10 | 2021-08-23 | Янссен Вэксинс Энд Превеншн Б.В. | Полипептид стеблевого домена гемагглютинина вируса гриппа и его применение |
| CN106714800B (zh) | 2014-07-11 | 2021-09-03 | 吉利德科学公司 | 用于治疗hiv的toll样受体调节剂 |
| EP3169352A1 (de) | 2014-07-15 | 2017-05-24 | Immune Design Corp. | Prime-boost-therapieschemata mit einem tlr4-agonist-adjuvans und einem lentivirusvektor |
| RU2714248C2 (ru) | 2014-07-23 | 2020-02-13 | Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд | Варианты фактор н-связывающего белка и способы их применения |
| BR102015023450A2 (pt) | 2014-09-16 | 2016-04-12 | Gilead Sciences Inc | formas sólidas de um modulador do receptor semelhante a toll |
| MX2017003288A (es) | 2014-09-16 | 2017-06-28 | Gilead Sciences Inc | Metodos para preparar modulares de receptor tipo toll. |
| JP7095990B2 (ja) | 2014-09-18 | 2022-07-05 | シーダーズ－サイナイ メディカル センター | 線維症を治療するための組成物及び方法 |
| HUE040440T2 (hu) | 2014-11-04 | 2019-03-28 | Janssen Vaccines & Prevention Bv | Terápiás HPV16-oltóanyagok |
| MA40920A (fr) | 2014-11-07 | 2017-09-12 | Takeda Vaccines Inc | Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| CA2966794C (en) | 2014-11-12 | 2023-03-14 | Lamberti Spa | Method of increasing lubricity of wellbore fluids |
| EP3218002B1 (de) | 2014-11-13 | 2020-08-19 | Evaxion Biotech ApS | Aus acinetobacter baumannii abgeleitete peptide und deren verwendung bei der impfung |
| ES2861806T3 (es) | 2014-12-02 | 2021-10-06 | Novartis Ag | Fabricación de composiciones que contienen tensioactivo |
| EP3031822A1 (de) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus-Antigene |
| EP3244918A2 (de) | 2015-01-12 | 2017-11-22 | Evaxion Biotech ApS | Proteine und nukleinsäuren zur verwendung für impfstoffe gegen klebsiella pneumoniae |
| EP3047856A1 (de) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv-antigene und ihre verwendungen |
| MX2017010705A (es) | 2015-02-19 | 2017-12-04 | Pfizer | Composiciones de neisseria meningitidis y metodos de la misma. |
| WO2016149771A1 (en) | 2015-03-26 | 2016-09-29 | Gamma Vaccines Pty Limited | Streptococcal vaccine |
| WO2016166088A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| CN114366802A (zh) | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
| US10624964B2 (en) | 2015-05-01 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs |
| IL255106B2 (en) | 2015-05-04 | 2023-04-01 | Pfizer | Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses |
| WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
| US11617724B2 (en) | 2015-05-21 | 2023-04-04 | Dermavant Sciences GmbH | Topical pharmaceutical compositions |
| RS63402B1 (sr) * | 2015-05-21 | 2022-08-31 | Dermavant Sciences GmbH | Topikalne farmaceutske kompozicije |
| JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
| EP4116316A1 (de) | 2015-07-04 | 2023-01-11 | Evaxion Biotech A/S | Proteine und nukleinsäuren, die in impfstoffen gegen pseudomonas aeruginosa nützlich sind |
| US10456462B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Preventions B.V. | Vaccine against RSV |
| WO2017005880A1 (en) | 2015-07-07 | 2017-01-12 | Seqirus UK Limited | Influenza potency assays |
| AU2016289496B2 (en) | 2015-07-07 | 2021-02-04 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| JP6889699B2 (ja) | 2015-07-29 | 2021-06-18 | アドバンスド バイオニュートリション コープ． | 特定栄養用途のための安定乾燥プロバイオティクス組成物 |
| WO2017029360A1 (en) | 2015-08-20 | 2017-02-23 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv18 vaccines |
| CA2996762A1 (en) | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
| US10538557B2 (en) | 2015-09-02 | 2020-01-21 | Janssen Vaccines & Prevention B.V. | Stabilized viral class I fusion proteins |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| EP3374373B1 (de) | 2015-11-09 | 2022-12-21 | Immune Design Corp. | Retroviraler vektor zur verabreichung und expression von replikon-rna-exprimierenden heterologen nukleinsäuren |
| EA201890861A1 (ru) | 2015-11-09 | 2018-10-31 | Иммьюн Дизайн Корп. | Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения |
| CN105251002B (zh) * | 2015-11-13 | 2019-02-15 | 中国人民解放军第三军医大学 | 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法 |
| JP6817307B2 (ja) | 2015-12-23 | 2021-01-20 | ファイザー・インク | Ｒｓｖ ｆタンパク質突然変異体 |
| EP3405212B1 (de) | 2016-01-19 | 2020-07-08 | Pfizer Inc | Impfstoffe gegen krebs |
| EP3419654B1 (de) | 2016-02-22 | 2022-04-27 | Evaxion Biotech A/S | In impfstoffen gegen staphylococcus aureus nützliche proteine und nukleinsäuren |
| JP2019509275A (ja) | 2016-02-23 | 2019-04-04 | イミューン デザイン コーポレイション | マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム |
| CA3016867A1 (en) | 2016-03-11 | 2017-09-14 | Pfizer Inc. | Human cytomegalovirus gb polypeptide |
| WO2017162741A1 (en) * | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection |
| MD3439672T2 (ro) | 2016-04-05 | 2021-04-30 | Janssen Vaccines & Prevention Bv | Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV |
| MY193584A (en) | 2016-04-05 | 2022-10-19 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
| WO2017192418A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| EA039124B1 (ru) | 2016-05-30 | 2021-12-08 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные f-белки rsv до слияния |
| WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| WO2017216384A1 (en) | 2016-06-17 | 2017-12-21 | Evaxion Biotech Aps | Vaccination targeting ichthyophthirius multifiliis |
| EP3472327B1 (de) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potenter und ausbalancierter bidirektionaler promotor |
| WO2017220753A1 (en) | 2016-06-22 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
| EP3269385A1 (de) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung |
| WO2017220787A1 (en) | 2016-06-24 | 2017-12-28 | Evaxion Biotech Aps | Vaccines against aearomonas salmonicida infection |
| WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| US11414464B2 (en) | 2016-07-22 | 2022-08-16 | Evaxion Biotech A/S | Chimeric proteins for inducing immunity towards infection with S. aureus |
| BR112019001486B1 (pt) | 2016-07-28 | 2024-02-27 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Sacarídeo, composição de vacina compreendendo o mesmo e composto intermediário para a síntese de dito sacarídeo |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US20210108002A1 (en) | 2016-12-06 | 2021-04-15 | Glaxosmithkline Biologicals Sa | Purification Process For Capsular Polysaccharide |
| WO2018127545A1 (en) | 2017-01-05 | 2018-07-12 | Evaxion Biotech Aps | Vaccines targeting pseudomonas aeruginosa |
| EP3576759A4 (de) | 2017-01-31 | 2020-11-11 | Merck Sharp & Dohme Corp. | Verfahren zur herstellung von kapselpolysaccharidproteinkonjugaten aus streptococcus pneumoniae serotyp 19f |
| SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| CA3053212C (en) | 2017-02-09 | 2021-04-13 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
| GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
| MX2019011599A (es) | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
| WO2018183666A1 (en) | 2017-03-31 | 2018-10-04 | Boston Medical Center Corporation | Methods and compositions using highly converved pneumococcal surface proteins |
| EP3624844A1 (de) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Verfahren und zusammensetzungen zur induzierung schützender immunität gegen rsv-infektionen |
| SG11201911930SA (en) | 2017-06-11 | 2020-01-30 | Molecular Express Inc | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
| AU2018290298B2 (en) | 2017-06-23 | 2024-03-28 | Affinivax, Inc. | Immunogenic compositions |
| WO2019050815A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
| SG11202002174SA (en) | 2017-09-13 | 2020-04-29 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
| US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| KR20240145065A (ko) | 2017-10-25 | 2024-10-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 인산화 타우 펩티드의 조성물 및 이의 용도 |
| CN111511395B (zh) | 2017-11-03 | 2024-10-15 | 武田疫苗股份有限公司 | 用于将寨卡病毒灭活和用于确定灭活完全性的方法 |
| AU2018400751B2 (en) | 2017-12-06 | 2022-07-21 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| WO2019145310A1 (en) | 2018-01-23 | 2019-08-01 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| WO2019145399A1 (en) | 2018-01-24 | 2019-08-01 | Evaxion Biotech Aps | Vaccines for prophylaxis of s. aureus infections |
| WO2019173438A1 (en) | 2018-03-06 | 2019-09-12 | Stc. Unm | Compositions and methods for reducing serum triglycerides |
| TW202003023A (zh) | 2018-03-12 | 2020-01-16 | 美商詹森藥物公司 | 針對尿路感染之疫苗 |
| IL312725A (en) | 2018-04-09 | 2024-07-01 | Eisai R&D Man Co Ltd | Palladianolide compounds and their use |
| BR112020020956A2 (pt) | 2018-04-12 | 2021-03-02 | Eisai R&D Management Co., Ltd. | derivados de pladienolida como spliceossoma que tem como alvo agentes para tratar câncer |
| GB201807303D0 (en) | 2018-05-03 | 2018-06-20 | London School Of Hygeine & Tropical Medicine | Glyconjugate vaccines |
| WO2019224275A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2019227022A1 (en) | 2018-05-25 | 2019-11-28 | Bioventures, Llc | Myxoma virus compositions and methods of use |
| EP3574915A1 (de) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität |
| JOP20200268A1 (ar) | 2018-06-01 | 2020-10-26 | Eisai R&D Man Co Ltd | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها |
| WO2019232433A2 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| BR112020025765A2 (pt) | 2018-06-22 | 2021-03-16 | Synformulas Gmbh | Bactérias bifidobacterium bifidum não viáveis e uso destas |
| US20210220462A1 (en) | 2018-08-23 | 2021-07-22 | Glaxosmithkline Biologicals Sa | Immunogenic proteins and compositions |
| EP3870207A1 (de) | 2018-10-22 | 2021-09-01 | Evaxion Biotech ApS | Impfstoff gegen m. catharrhalis |
| KR20210091749A (ko) | 2018-11-13 | 2021-07-22 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합전 rsv f 단백질 |
| US20220031859A1 (en) | 2018-12-13 | 2022-02-03 | Eisai R&D Management Co., Ltd. | Herboxidiene antibody-drug conjugates and methods of use |
| AU2019401535B2 (en) | 2018-12-19 | 2023-12-14 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| EP3908302A1 (de) | 2019-01-10 | 2021-11-17 | Expres2ion Biotechnologies ApS | Glyco-modifizierte immunisierungsantigene |
| EP3917567A1 (de) | 2019-01-30 | 2021-12-08 | GlaxoSmithKline Biologicals SA | Öl-/tensidmischungen zur selbstemulgierung |
| CA3129252A1 (en) | 2019-02-08 | 2020-08-13 | Ac Immune S.A. | Method of safe administration of phosphorylated tau peptide vaccine |
| EP3931206A1 (de) | 2019-02-27 | 2022-01-05 | Evaxion Biotech ApS | Impfstoffe gegen h. influenzae |
| SG11202111770RA (en) | 2019-04-24 | 2021-11-29 | Janssen Pharmaceuticals Inc | Heterologous administration of tau vaccines |
| EP3959228A1 (de) | 2019-04-25 | 2022-03-02 | Janssen Vaccines & Prevention B.V. | Rekombinante influenza-antigene |
| CA3140234A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
| KR20220008875A (ko) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여 |
| US20220249646A1 (en) | 2019-05-25 | 2022-08-11 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
| EP3999093A4 (de) | 2019-07-19 | 2023-11-22 | Merck Sharp & Dohme LLC | Antigene glykoprotein-e-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| EP3770269A1 (de) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantifizierung von biokonjugatglykosylierung |
| CN114728050A (zh) | 2019-07-31 | 2022-07-08 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法 |
| AU2020342463A1 (en) | 2019-09-05 | 2022-03-24 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| WO2021048381A1 (en) | 2019-09-13 | 2021-03-18 | Evaxion Biotech Aps | Method for identifying stable mhc binding peptides using mass spectrometry |
| US20220334129A1 (en) | 2019-09-13 | 2022-10-20 | Evaxion Biotech A/S | Method for identifying T-cell epitopes |
| EP3799884A1 (de) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogene zusammensetzungen |
| WO2021067785A1 (en) | 2019-10-02 | 2021-04-08 | Janssen Vaccines & Prevention B.V | Staphylococcus peptides and methods of use |
| CN115380107A (zh) | 2019-11-18 | 2022-11-22 | 思齐乐私人有限公司 | 用于产生重配流感病毒的方法 |
| US20230050225A1 (en) | 2020-01-06 | 2023-02-16 | Evaxion Biotech A/S | Vaccines targeting Neisseria gonorrhoeae |
| WO2021141456A1 (ko) | 2020-01-10 | 2021-07-15 | 주식회사 엘지화학 | Mhc 및 종양 항원을 동시 발현하는 항원제시세포를 포함하는 조성물 및 이를 이용한 암 치료 |
| PT4090363T (pt) | 2020-01-16 | 2024-09-19 | Janssen Pharmaceuticals Inc | Mutante de fimh, composições com o mesmo e sua utilização |
| NL2030835B1 (en) | 2020-01-24 | 2022-12-29 | Aim Immunotech Inc | Methods, compositions, and vaccinces for treating a virus infection |
| BR102020002165A2 (pt) | 2020-01-31 | 2021-11-30 | Fundação Oswaldo Cruz | Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas. |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| WO2021163448A2 (en) | 2020-02-13 | 2021-08-19 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for detecting and preventing filariasis |
| CN115175924A (zh) | 2020-02-26 | 2022-10-11 | 港大科桥有限公司 | 基于pd-1的针对冠状病毒感染的疫苗 |
| CA3175521A1 (en) | 2020-04-16 | 2021-10-21 | Par'immune Sas | 28 kda gst proteins from schistosoma for the treatment of vasculitis |
| WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
| EP3900739A1 (de) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein |
| US20210347828A1 (en) | 2020-05-11 | 2021-11-11 | Janssen Pharmaceuticals, Inc. | RNA Replicon Encoding a Stabilized Corona Virus Spike Protein |
| IL298055A (en) | 2020-05-11 | 2023-01-01 | Janssen Pharmaceuticals Inc | Stabilized coronavirus spike protein fusion proteins |
| CA3183500A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| WO2022002894A1 (en) | 2020-06-29 | 2022-01-06 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
| EP4171629A1 (de) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvans |
| US20230218526A1 (en) | 2020-06-30 | 2023-07-13 | Seqirus UK Limited | Cold filtration of oil-in-water emulsion adjuvants |
| MX2023000373A (es) | 2020-07-06 | 2023-02-13 | Janssen Pharmaceuticals Inc | Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas. |
| US20230260594A1 (en) | 2020-07-30 | 2023-08-17 | Evaxion Biotech A/S | Process for preparation of neopepitope-containing vaccine agents |
| EP4203995A1 (de) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon |
| IL301402A (en) | 2020-09-17 | 2023-05-01 | Inst Nat Sante Rech Med | An immunogenic product containing a segment of ige for the treatment of inflammatory disorders mediated by ige |
| JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| CN112403140B (zh) * | 2020-10-19 | 2022-07-19 | 傅光明 | 一种消烟除尘剂及其制备方法 |
| CN117202928A (zh) | 2020-11-13 | 2023-12-08 | Icosavax股份有限公司 | 用于偏肺病毒的基于蛋白质的纳米颗粒疫苗 |
| EP4277921A1 (de) | 2021-01-12 | 2023-11-22 | Janssen Pharmaceuticals, Inc. | Fimh-mutanten, zusammensetzungen damit und verwendung davon |
| US20240115674A1 (en) | 2021-02-03 | 2024-04-11 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for preventing filariasis and dirofilariasis |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| IL305313A (en) | 2021-02-19 | 2023-10-01 | Sanofi Pasteur | Recombinant meningococcal B vaccine |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CA3211449A1 (en) | 2021-02-24 | 2022-09-01 | Pfizer Inc. | Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof |
| CA3215752A1 (en) | 2021-04-01 | 2022-10-06 | Janssen Pharmaceuticals, Inc. | Production of e. coli o18 bioconjugates |
| EP4314019A2 (de) | 2021-04-01 | 2024-02-07 | Janssen Vaccines & Prevention B.V. | Stabilisierte präfusionierte piv3 f-proteine |
| WO2022234483A1 (en) | 2021-05-04 | 2022-11-10 | King Abdullah University Of Science And Technology | Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof |
| WO2022248531A1 (en) | 2021-05-26 | 2022-12-01 | Evaxion Biotech A/S | Vaccination targeting intracellular pathogens |
| WO2022261251A1 (en) | 2021-06-08 | 2022-12-15 | Glyde Bio Inc. | Immunogenic compositions comprising tumour-associated antigen |
| CN117915944A (zh) | 2021-07-05 | 2024-04-19 | 伊沃逊生物科技股份公司 | 靶向淋病奈瑟氏菌的疫苗 |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| CN115106200B (zh) * | 2021-10-25 | 2024-06-21 | 中国矿业大学(北京) | 一种选煤复配捕收剂及其制备方法和煤泥浮选方法 |
| WO2023079528A1 (en) | 2021-11-05 | 2023-05-11 | King Abdullah University Of Science And Technology | Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses |
| WO2023079529A1 (en) | 2021-11-05 | 2023-05-11 | King Abdullah University Of Science And Technology | Re-focusing protein booster immunization compositions and methods of use thereof |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (de) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilisierte präfusions-hmpv-fusionsproteine |
| AU2022409746A1 (en) | 2021-12-17 | 2024-07-04 | Evaxion Biotech A/S | Personalized cancer therapy targeting normally non-expressed sequences |
| CN118302193A (zh) | 2022-01-25 | 2024-07-05 | 株式会社新日本科学 | 佐剂组合物及疫苗组合物 |
| WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2023213393A1 (en) | 2022-05-04 | 2023-11-09 | Evaxion Biotech A/S | Staphylococcal protein variants and truncates |
| WO2023217988A1 (en) | 2022-05-12 | 2023-11-16 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023225562A1 (en) | 2022-05-17 | 2023-11-23 | Icosavax, Inc. | Multivalent vaccine for paramyxoviruses and uses thereof |
| WO2024017682A1 (en) | 2022-07-18 | 2024-01-25 | Janssen Vaccines & Prevention B.V. | Rsv immunogens |
| WO2024018061A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Use of bordetella strains for the treatment of chronic obstructive pulmonary disease |
| WO2024030856A2 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024061753A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
| WO2024104947A2 (en) | 2022-11-14 | 2024-05-23 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
| WO2024105236A1 (en) | 2022-11-17 | 2024-05-23 | Expres2Ion Biotechnologies Aps | Recombinant production of protein having xylosylated n-glycans |
| WO2024130009A1 (en) | 2022-12-14 | 2024-06-20 | Yale University | Compositions and methods of use thereof for the treatment of virally driven cancers |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
| US20240269263A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
| WO2024170669A1 (en) | 2023-02-15 | 2024-08-22 | Futrue R&S 2 Gmbh | Multi-strain probiotic preparation for the treatment of immunological and allergic disorders |
| WO2024175579A1 (en) | 2023-02-21 | 2024-08-29 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain |
| WO2024180262A1 (en) | 2023-03-02 | 2024-09-06 | Sanofi | Compositions for use in treatment of chlamydia |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2008856A (en) * | 1935-07-23 | Cash begisteb | ||
| GB888180A (de) * | 1900-01-01 | |||
| US2017507A (en) * | 1934-06-29 | 1935-10-15 | Ruth L Moehling | Shoe cover |
| DE1792410B2 (de) * | 1967-09-01 | 1980-03-13 | Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm | Arzneimittelzubereitung zur intravenösen Injektion |
| US3790665A (en) | 1968-02-23 | 1974-02-05 | Haver Lockhart Labor Inc | Injectable adjuvant,method of preparing same and compositions including such adjuvant |
| US3678149A (en) * | 1970-01-26 | 1972-07-18 | Samuel J Prigal | Method of enhancing the action of a medicament |
| US3833743A (en) * | 1970-03-17 | 1974-09-03 | Merck & Co Inc | Solubilization of water and aqueous solutions in non-aqueous liquids |
| US3919411A (en) * | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
| FR2428051A1 (fr) * | 1978-06-05 | 1980-01-04 | Anvar | Nouveaux composes du type muramyl-peptide et medicaments les contenant |
| JPS5810365B2 (ja) * | 1978-09-08 | 1983-02-25 | 田辺製薬株式会社 | 脂肪乳剤 |
| US4409209A (en) * | 1979-10-12 | 1983-10-11 | Ciba-Geigy Corporation | Novel phosphorylmuramyl peptides and processes for the manufacture thereof |
| FI803077A (fi) * | 1979-10-12 | 1981-04-13 | Ciba Geigy Ag | Foerfarande foer framstaellning av myramylpeptider |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0114787B1 (de) * | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| JPS601122A (ja) * | 1983-06-20 | 1985-01-07 | Green Cross Corp:The | ビフエニリルプロピオン酸誘導体脂肪乳剤 |
| FR2551758B1 (fr) * | 1983-08-16 | 1986-01-31 | Anvar | Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages |
| US4770874A (en) * | 1983-08-22 | 1988-09-13 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| FR2564096B1 (fr) * | 1984-05-11 | 1988-02-19 | Anvar | Derives lipophiles de muramylpeptides ayant des proprietes d'activation des macrophages, compositions les contenant et procede pour les obtenir |
| US4784845A (en) * | 1985-09-16 | 1988-11-15 | American Cyanamid Company | Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs |
| DK585886A (da) * | 1985-12-24 | 1987-06-25 | Takeda Chemical Industries Ltd | Immunstimulerende middel og anvendelse deraf |
| US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
| US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
| NZ221306A (en) * | 1986-08-15 | 1990-02-26 | Commw Scient Ind Res Org | 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof |
| US5376369A (en) * | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
| ZA888209B (en) | 1987-11-03 | 1990-07-25 | Syntex Inc | Vaccine adjuvant |
| US4950645A (en) * | 1988-07-08 | 1990-08-21 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| EP0382271B1 (de) | 1989-02-04 | 1994-12-21 | Akzo Nobel N.V. | Tocole als Impfstoffadjuvans |
| US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
| EP0640348A1 (de) * | 1993-07-26 | 1995-03-01 | Akzo Nobel N.V. | Adjuvansmischung auf Ölbasis und auf Wasserbasis |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| DK1042001T3 (da) * | 1997-12-16 | 2002-07-08 | Chiron Corp | Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner |
-
1990
- 1990-05-24 CA CA002017507A patent/CA2017507C/en not_active Expired - Lifetime
- 1990-05-24 HU HU905459A patent/HU212924B/hu active Protection Beyond IP Right Term
- 1990-05-24 JP JP2509214A patent/JPH0832638B2/ja not_active Expired - Lifetime
- 1990-05-24 WO PCT/US1990/002954 patent/WO1990014837A1/en unknown
- 1990-05-25 PT PT94168A patent/PT94168B/pt not_active IP Right Cessation
- 1990-05-25 EP EP90305744A patent/EP0399843B1/de not_active Revoked
- 1990-05-25 DE DE199090305744T patent/DE399843T1/de active Pending
- 1990-05-25 IE IE190390A patent/IE64766B1/en active Protection Beyond IP Right Term
- 1990-05-25 ES ES90305744T patent/ES2033626T3/es not_active Expired - Lifetime
- 1990-05-25 DE DE69010574T patent/DE69010574T2/de not_active Revoked
- 1990-05-25 DK DK90305744.6T patent/DK0399843T5/da active
- 1990-05-25 DD DD90341001A patent/DD294633A5/de unknown
- 1990-05-25 AT AT90305744T patent/ATE108327T1/de not_active IP Right Cessation
-
1991
- 1991-11-15 GR GR91300063T patent/GR910300063T1/el unknown
-
1995
- 1995-04-07 US US08/418,870 patent/US6299884B1/en not_active Expired - Lifetime
- 1995-05-04 US US08/434,512 patent/US6451325B1/en not_active Expired - Lifetime
- 1995-07-06 HK HK107695A patent/HK107695A/xx not_active IP Right Cessation
-
2002
- 2002-09-17 US US10/246,195 patent/US20090191226A2/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT94168A (pt) | 1991-01-08 |
| EP0399843B1 (de) | 1994-07-13 |
| IE64766B1 (en) | 1995-09-06 |
| ES2033626T3 (es) | 1994-10-16 |
| HU212924B (en) | 1996-12-30 |
| IE901903L (en) | 1990-11-25 |
| DD294633A5 (de) | 1991-10-10 |
| JPH0832638B2 (ja) | 1996-03-29 |
| WO1990014837A1 (en) | 1990-12-13 |
| HUT61203A (en) | 1992-12-28 |
| HU905459D0 (en) | 1992-02-28 |
| DE69010574D1 (de) | 1994-08-18 |
| DK0399843T5 (da) | 1994-09-19 |
| EP0399843A2 (de) | 1990-11-28 |
| GR910300063T1 (en) | 1991-11-15 |
| JPH05508385A (ja) | 1993-11-25 |
| CA2017507C (en) | 1996-11-12 |
| ES2033626T1 (es) | 1993-04-01 |
| DE69010574T2 (de) | 1994-10-27 |
| US6299884B1 (en) | 2001-10-09 |
| HK107695A (en) | 1995-07-14 |
| ATE108327T1 (de) | 1994-07-15 |
| PT94168B (pt) | 2001-05-31 |
| EP0399843A3 (de) | 1992-09-02 |
| US20090191226A2 (en) | 2009-07-30 |
| CA2017507A1 (en) | 1990-11-25 |
| US20030147898A1 (en) | 2003-08-07 |
| US6451325B1 (en) | 2002-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE399843T1 (de) | Hilfsmittelformulierung die eine emulsion mit submikronischen oeltropfen enthaelt. | |
| DE3685519T2 (de) | Influenzaimpfstoff. | |
| JP2557603B2 (ja) | ワクチン組成物 | |
| JP3888470B2 (ja) | 乳化したペトロラタムを含有する皮膚保護組成物 | |
| Tsugita et al. | Studies on OW emulsions stabilized with insoluble montmorillonite-organic complexes | |
| DE69314020T2 (de) | Impfstoffe die nicht ionische tensid vesikeln enthalften | |
| DE69320980T2 (de) | Verfahren zur herstellung von phytosphingosin-enthaltenden ceramiden und kosmetische zusammensetzungen, die diese enthalten | |
| DE69131709T2 (de) | Liposomen enthaltende impfstoffzusammensetzungen | |
| US5079227A (en) | Perfume composition, with a continuous aqueous phase, having a high concentration of perfume | |
| GB2047563A (en) | Emulsifier composition | |
| EP0279641B1 (de) | Kosmetische Präparate | |
| DE59002618D1 (de) | Verfahren zur Herstellung einer Nanoemulsion von Oelpartikeln in einer wässrigen Phase. | |
| JPS59203633A (ja) | 高粘度の水中油型ミクロエマルジョン及びその製造方法 | |
| DE59108594D1 (de) | Verfahren zur herstellung von reinigungs- und pflegemitteln | |
| CN107106490B (zh) | 用于制作气溶胶的乳化组合物及气溶胶剂 | |
| Alander et al. | Model microemulsions containing vegetable oils 2. Ionic surfactant systems | |
| DE69414779T2 (de) | Reinigungsmittel in Form einer stabilen Mikroemulsion | |
| Friberg et al. | The mechanism of hydrotrope action of a dicarboxylic acid | |
| JPS5716818A (en) | Steroid fatty emulsion | |
| US4474912A (en) | Stable water-in-oil emulsions containing polyoxyalkylene block copolymers | |
| EP1056712A4 (de) | 12-hydroxy-stearinsäureester, darauf basierende zusammensetzungen und methoden zur anwendung und herstellung dieser zusammensetzungen | |
| DE19514269A1 (de) | Antitranspirantien | |
| Berlin | Gross physical properties of emulsified influenza virus vaccines and the adjuvant response | |
| JPH0899832A (ja) | 皮膚用乳化化粧料 | |
| Pithapurwala et al. | Solubilization and fluorescence behavior of petroleum sulfonate containing microemulsions |